Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer

Project: Research project

Description

we propose two translational
objectives embedded in the clinical trial:
Aim 1: Measure the antigen burden induced by
treatment with guadecitabine in human tumors in
relationship to clinical response.
Aim 2: Determine the anti-tumor activity of CD8+
effector T cells induced by treatment with
guadecitabine and pembrolizumab in relationship to
clinical response.
We will take advantage of the unique resource provided by the ready-to-activate investigator initiated phase II
clinical trial testing the combination of pembrolizumab and guadecitabine (SGI-110) in women with platinum
resistant OC and measure tumor antigen expression and immune activation in tumor biopsies obtained before
and after treatment.
StatusActive
Effective start/end date5/1/174/30/20

Funding

  • U.S. Army Medical Research and Materiel Command (W81XWH-17-1-0141)

Fingerprint

Epigenomics
Ovarian Neoplasms
Immunotherapy
Neoplasms
Neoplasm Antigens
Research Personnel
Clinical Trials
T-Lymphocytes
Biopsy
Antigens
Therapeutics
SGI-110
pembrolizumab